1. Introduction {#sec1-biomolecules-09-00091}
===============

Immuno-positron emission tomography (PET) is of great value for the development of monoclonal antibodies (mAbs) as therapeutic targeting vectors, enabling tracking and quantification of radiolabeled mAbs at high resolution and sensitivity \[[@B1-biomolecules-09-00091]\]. In recent years, Zirconium-89 (^89^Zr), in particular, has become the most commonly-studied positron-emitting radionuclide for immuno-PET imaging. The physical half-life of 78.4 h is a good match with the biological half-life of mAbs, thus increasing the utility of PET in the development of this class of compound, and its medium mean positron energy of 0.395 MeV allows high-resolution PET imaging \[[@B2-biomolecules-09-00091]\]. Additionally, in contrast to iodine-124, another long-lived positron-emitter, which has a rapid release of radioiodine from the cell after internalization, ^89^Zr is a residualizing radiometal and facilitates the visualization of tumors \[[@B3-biomolecules-09-00091]\]. As an osteophilic radionuclide, immuno-PET imaging with ^89^Zr requires stable coordination of the radionuclide with the chelator to minimize dissociation resulting in bone accumulation in vivo.

To date, desferrioxamine B (DFO), see [Figure 1](#biomolecules-09-00091-f001){ref-type="fig"}, has been the most widely used bifunctional chelating system for ^89^Zr-based radiopharmaceuticals. Although chelation with DFO results in complexes with acceptable stability in pre-clinical as well as some clinical studies, it is far from being optimal due to the partial release of \[^89^Zr\]Zr^4+^ from the chelating system \[[@B4-biomolecules-09-00091]\]. The released \[^89^Zr\]Zr^4+^ has been reported to accumulate in bone, particularly at late time points (3--7 days), which results in a decrease in image contrast, as well as an increase in radiation dose, especially to bone marrow \[[@B5-biomolecules-09-00091],[@B6-biomolecules-09-00091],[@B7-biomolecules-09-00091],[@B8-biomolecules-09-00091],[@B9-biomolecules-09-00091],[@B10-biomolecules-09-00091]\]. The instability of DFO is attributed to the linear structure (which allows easy access to challenging cations and natural chelators in vivo), as well as to the incomplete saturation of the 8-coordination sphere of Zr^4+^ \[[@B11-biomolecules-09-00091]\]. The development of novel high-stability Zr^4+^-ligands to minimize the uptake of liberated Zr^4+^ in the bone and other non-targeted tissue is an interesting and important goal. While many investigators focus on the optimization of the conjugation moiety between DFO and the biomolecule, attempts to develop new chelators are increasing \[[@B12-biomolecules-09-00091],[@B13-biomolecules-09-00091],[@B14-biomolecules-09-00091],[@B15-biomolecules-09-00091],[@B16-biomolecules-09-00091],[@B17-biomolecules-09-00091],[@B18-biomolecules-09-00091],[@B19-biomolecules-09-00091],[@B20-biomolecules-09-00091],[@B21-biomolecules-09-00091],[@B22-biomolecules-09-00091]\]. Several novel octadentate and oxygen-rich ^89^Zr-chelators have been reported showing improved in vitro stability. These novel chelators are designed to be acyclic or macrocyclic by the addition of another hydroxamate unit \[[@B12-biomolecules-09-00091],[@B13-biomolecules-09-00091],[@B17-biomolecules-09-00091],[@B19-biomolecules-09-00091],[@B21-biomolecules-09-00091]\] or introduce new chelating groups such as hydroxypyridinone and pyrocatechol groups \[[@B14-biomolecules-09-00091],[@B15-biomolecules-09-00091],[@B16-biomolecules-09-00091],[@B20-biomolecules-09-00091]\].

Recently, we reported that fusarinine C (FSC), which has a 36-membered ring structure and three bidentate hydroxamates to coordinate ^89^Zr, showed superior stability and kinetic inertness compared to DFO. In particular, the excellent targeting properties of FSC bioconjugates in PET-imaging studies showed FSC to be a highly promising alternative chelator for ^89^Zr \[[@B23-biomolecules-09-00091],[@B24-biomolecules-09-00091],[@B25-biomolecules-09-00091]\]. However, since FSC is hexadentate rather than octadentate, we postulated that improvements could be expected by introducing additional coordinating groups to saturate the coordination sphere of \[^89^Zr\]Zr^4+^. Another potential drawback of FSC as a ^89^Zr-bifunctional chelator lies in it having three functionalities for derivatization, which, despite facilitating the employment of multivalent concepts for small molecules, are not suitable for conjugation to macromolecules, especially antibodies. Therefore, a further aim of this study was to design a FSC-based mono-functional ^89^Zr-chelator. As proof of concept, modifications via succinic acid derivatization resulting in FSC(succ)~2~ acetic anhydride (AA) and FSC(succ)~3~, see [Figure 1](#biomolecules-09-00091-f001){ref-type="fig"}, were developed. This straightforward modification introduces additional carboxylic acid groups known to coordinate with Zr, which additionally can be utilized for bioconjugation strategies. In this study, the in vitro stability and transchelation properties of these ^89^Zr-complexes were investigated and compared with \[^89^Zr\]Zr-DFO and ^89^Zr-triacetylfusarinine C (\[^89^Zr\]Zr-TAFC). The in vivo properties of \[^89^Zr\]Zr-FSC(succ)~3~ were further compared with \[^89^Zr\]Zr-TAFC in BALB/c mice.

2. Materials and Methods {#sec2-biomolecules-09-00091}
========================

All commercially available reagents were of reagent grade and used as supplied with no further purification. Desferrioxamine B was obtained from Genaxxon Bioscience GmbH (Ulm, Germany). Triacetylfusarinine C was prepared and purified as described previously \[[@B23-biomolecules-09-00091]\]. \[^89^Zr\]Zr-oxalate was purchased from Perkin Elmer, Inc (Waltham, MA, US) with an activity concentration of 900--1000 MBq per milliliter.

Purification of compounds was performed via a preparative reversed-phase high-performance liquid chromatography system (preparative RP-HPLC) using a Gilson 322 HPLC pump, a Gilson ultraviolet (UV)/VIS-155 detector (Gilson International B.V., Limburg, Germany), and a Eurosil Bioselect Vertex Plus 300 × 8 mm 5 μm C~18A~ 300 Å column (Knauer, Berlin, Germany) with a flow rate of 3.0 mL/min. The gradient was as follows: 0--1.0 min 10% acetonitrile (CH~3~CN), 1.0--18.0 min 10--40% CH~3~CN (gradient A).

Analytical RP-HPLC analysis was performed with an UltiMate 3000 RS HPLC pump, an UltiMate 3000 RS column compartment (column oven temperature was set at 25 °C), an UltiMate 3000 UV-Vis variable wavelength detector (Dionex, Gemering, Germany), and a Raytest radiometric detector (Raytest GmbH, Straubenhardt, Germany). A Vydac 218 TP5215, 150 × 3.0 mm column (SRD, Vienna, Austria), flow rate 1.0 mL/min, and UV-Vis detection at 220/410 nm were employed with the following CH~3~CN/H~2~O/0.1% trifluoroacetic acid (TFA) gradient: 0--0.5 min 0% CH~3~CN/0.1% TFA, 0.5--7.0 min, 0--55% CH~3~CN/0.1% TFA (gradient B).

2.1. Fusarinine C {#sec2dot1-biomolecules-09-00091}
-----------------

Fusarinine C was produced as described previously \[[@B23-biomolecules-09-00091]\]. Briefly, the *Aspergillus fumigatus* mutant strain *∆sidG* was cultured in iron-free minimal medium with 1% glucose for 36 h at 37 °C and 200 rpm. Biomass was removed by filtration. The media-containing siderophore was collected and concentrated. Additional purification was performed via preparative RP-HPLC (gradient A, t~R~ = 10.2 min) followed by concentration and lyophilization. Analytical RP-HPLC (gradient B): t~R~ = 4.7 min.

2.2. Fusarinine C (succ)~3~ {#sec2dot2-biomolecules-09-00091}
---------------------------

To FSC (50 mg, 69 µmol) dissolved in 1 mL dimethylformamide (DMF), 34.5 mg of succinic anhydride (5 eq, 0.34 mmol) was added and the pH was adjusted to 4.5 using *N*,*N*-diisopropylethylamine (DIPEA). After shaking for 0.5 h, FSC(succ)~3~ was directly isolated via preparative RP-HPLC (gradient A, t~R~ = 12.1 min) and confirmed by matrix-assisted laser desorption/ionization time of flight mass spectrometry (MALDI-TOF-MS). The collected fractions were concentrated and lyophilized. FSC(succ)~3~: yield: 63 mg, (61 µmol), 88%; MALDI TOF-MS: \[M + H\]^+^ = 1028.2 \[C~45~H~66~N~6~O~21~; exact mass: 1026.4 (calculated)\]. Analytical RP-HPLC (gradient B): t~R~ = 5.6 min.

2.3. Fusarinine C(succ)~2~ {#sec2dot3-biomolecules-09-00091}
--------------------------

The general synthesis procedure of FSC(succ)~2~ was the same as that of FSC(succ)~3~ except that a 2 eq molar excess of succinic anhydride was used. FSC(succ)~2~ was isolated from the byproducts (FSC-succ and FSC(succ)~3~) via preparative RP-HPLC (gradient A, t~R~ = 11.5 min). FSC(succ)~2~: yield: 28 mg, (30 µmol), 43%. MALDI TOF-MS: \[M + H\]^+^ = 928.2 \[C~41~H~62~N~6~O~18~; exact mass: 926.4 (calculated)\]. Analytical RP-HPLC (gradient B): t~R~ = 5.4 min.

2.4. Fusarinine C(succ)~2~AA {#sec2dot4-biomolecules-09-00091}
----------------------------

To FSC(succ)~2~ (10 mg, 11 µmol) dissolved in 0.5 mL DMF, 1 mL of acetic anhydride (AA) was added. After shaking for 10 min, FSC(succ)~2~AA was quickly isolated via preparative RP-HPLC (gradient A, t~R~ = 11.9 min) and confirmed by MALDI-TOF-MS. The collected fractions were concentrated and lyophilized. FSC(succ)~2~AA: yield: 9 mg, (9.3 µmol), 85%. MALDI TOF-MS: \[M + H\]^+^ = 970.1 \[C~43~H~64~N~6~O~19~; exact mass: 968.4 (calculated)\]. Analytical RP-HPLC (gradient B): t~R~ = 5.6 min.

2.5. Zr-Fusarinine C(succ)~2~AA and Zr-Fusarinine C(succ)~3~. {#sec2dot5-biomolecules-09-00091}
-------------------------------------------------------------

ZrCl~4~ (121 mg) was dissolved in 1 mL 0.1 M hydrochloric acid solution resulting in a concentration of 0.52 M. After dissolving FSC(succ)~2~AA (5 mg, 5.2 µmol) or FSC(succ)~3~ (5 mg, 4.9 µmol) in 1 mL water, a 1.2 eq molar excess of ZrCl~4~ (11.9 µL and 11.3 µL, respectively) was added. The reaction solutions were shaken gently for 5 min, then loaded onto a pre-activated Sep-Pak C~18~ cartridge. After washing the cartridge with 10 mL water, Zr-FSC(succ)~2~AA and Zr-FSC(succ)~3~ were eluted with 1mL methanol. The eluate fractions were dried by evaporation under nitrogen and weighed. The identities of the products were confirmed by electrospray ionization mass spectrometry (ESI-MS). Zr-FSC(succ)~2~AA: yield: 3.6 mg, (3.4 µmol), 65%. ESI-MS: \[M + H\]^+^ = 1,055.3 \[C~43~H~60~N~6~O~19~Zr, see [Figure 2](#biomolecules-09-00091-f002){ref-type="fig"}A; exact mass: 1054.3 (calculated)\]. RP-HPLC (gradient B): t~R~ = 5.4 min. Zr-FSC(succ)~3~: yield: 3.7 mg, (3.3 µmol), 67%. ESI-MS: \[M + H\]^+^ = 1113.3 \[C~45~H~62~N~6~O~21~Zr, see [Figure 2](#biomolecules-09-00091-f002){ref-type="fig"}B; exact mass: 1112.3 (calculated)\]. Analytical RP-HPLC (gradient B): t~R~ = 5.3 min.

2.6. ^89^Zr-Labeling {#sec2dot6-biomolecules-09-00091}
--------------------

Approximately 30 MBq (30 µL) of \[^89^Zr\]Zr-oxalate was mixed with 27 μL of sodium carbonate (Na~2~CO~3~, 1 M) and incubated for 3 min at room temperature (RT) \[[@B26-biomolecules-09-00091]\]. Thereafter, 100 μL of 4-(2-hydroxyethyl)-1-piperazineëthanesulfonic acid (HEPES) buffer (0.5 M, pH 7.0) was added to the reaction vial. Either DFO (32.8 μg), TAFC (42.6 μg), FSC(succ)~2~AA (48.5 μg) or FSC(succ)~3~ (51.4 μg) was added to the reaction vial. The labeling mixture was allowed to react at RT with a pH between 6.8 and 7.2 for 90 min. The reaction progress was monitored via analytical RP-HPLC (gradient B): \[^89^Zr\]Zr-DFO: t~R~ = 4.8 min, \[^89^Zr\]Zr-TAFC: t~R~ = 5.9 min, \[^89^Zr\]Zr-FSC(succ)~2~AA: t~R~ = 6.1 min, and \[^89^Zr\]Zr-FSC(succ)~3~: t~R~ = 6.0 min.

For animal experiments, 60 µL of CaCl~2~ (0.5 M) was added to the radiolabeling solution and a precipitate of Ca-oxalate appeared. The solution was then passed through a 0.2-µm filter to remove Ca-oxalate which may cause kidney failure. Subsequently, the filtrate was diluted to an appropriate volume using saline for administration to the BALB/c mice.

2.7. In Vitro Characterization {#sec2dot7-biomolecules-09-00091}
------------------------------

### 2.7.1. Distribution Coefficient {#sec2dot7dot1-biomolecules-09-00091}

A volume of 500 µL PBS including 0.5 MBq radioligand (\[^89^Zr\]Zr-FSC(succ)~2~AA or \[^89^Zr\]Zr-FSC(succ)~3~) was combined with 500 µL octanol. The mixture was vortexed for 15 min, and centrifuged for 2 min at 2000 rcf. Subsequently, 50 µL aliquots of the aqueous and the octanol layer were collected, measured in a 2480 Wizard^2^ Automatic Gamma Counter (Perkin Elmer, Vienna, Austria), and distribution coefficient (logD) values were calculated using Excel 2013 (*n* = 5) (Redmond, WA, USA).

### 2.7.2. Stability Assay {#sec2dot7dot2-biomolecules-09-00091}

Determination of the stability of \[^89^Zr\]Zr-DFO, \[^89^Zr\]Zr-TAFC, \[^89^Zr\]Zr-FSC(succ)~2~AA and \[^89^Zr\]Zr-FSC(succ)~3~ was carried out by incubating the radioligands in PBS, a 1000-fold molar excess of ethylenediaminetetraacetic acid (EDTA) solution (radioligand vs. EDTA: 25 µM vs. 25 mM) with different pH (pH 7, pH 6, and pH 4), as well as in human serum (the human serum was obtained from author C.D. with his consent at the Medical University Innsbruck within a routine blood withdrawal procedure) for seven days at 37 °C. At selected time points, PBS and EDTA samples were analyzed in triplicate directly via analytical RP-HPLC, while serum aliquots were mixed with 500 µL of CH~3~CN, vortexed, and centrifuged at 20,000 rcf for 2 min. Then, the precipitate was washed three times using CH~3~CN before analysis.

### 2.7.3. Transchelation Study {#sec2dot7dot3-biomolecules-09-00091}

\[^89^Zr\]Zr-DFO (50 µL) was mixed with a 1000-fold molar excess of either FSC(succ)~2~AA or FSC(succ)~3~ and \[^89^Zr\]Zr-TAFC (or \[^89^Zr\]Zr-FSC(succ)~2~AA, \[^89^Zr\]Zr-FSC(succ)~3~) (50 µL each) was mixed with a 1000-fold molar excess of DFO and incubated for seven days at RT. At selected time points, aliquots of the solutions were analyzed in triplicate directly via analytical RP-HPLC. The transchelation was determined by the ratio of \[^89^Zr\]Zr-DFO and \[^89^Zr\]Zr-FSC derivatives.

### 2.7.4. Protein Binding Assay {#sec2dot7dot4-biomolecules-09-00091}

The protein binding property was evaluated by incubating \[^89^Zr\]Zr-FSC(succ)~2~AA or \[^89^Zr\]Zr-FSC(succ)~3~ for seven days at 37 °C in fresh human serum. Subsequently, 30 µL of the solution was passed through a size exclusion spin column (MicroSpinG-50 column, GE Healthcare, Buckinghamshire, UK) via centrifugation at 2000 rcf for 2 min. Protein binding of the complexes in triplicate was determined by measuring the activity on the column (non-protein bound) and the activity in the eluate (protein bound) in the gamma counter.

### 2.7.5. Biodistribution Study {#sec2dot7dot5-biomolecules-09-00091}

All animal experiments were conducted in compliance with the Austrian animal protection laws and with the approval of the Austrian Ministry of Science (BMWFW-66.011/0049-WF/II/3b/2014) or were approved by the Animal Welfare and Ethical Review Body at Queen Mary University of London, and the UK Home Office (Project Licence 70/7603).

For the evaluation of biodistribution, four female BALB/c mice (Charles River Laboratories, Sulzfeld, Germany) were intravenously injected with \[^89^Zr\]Zr-FSC(succ)~3~ (1.5 MBq/mouse, 4.8 µg precursor) or \[^89^Zr\]Zr-TAFC (1.5 MBq/mouse, 4 µg) into the tail vein and sacrificed by cervical dislocation at 6 h post injection (p.i.). Organs (spleen, pancreas, stomach, intestine, kidney, liver, heart, and lung), blood, muscle tissue, and bone were dissected, weighed and then measured in the gamma counter to calculate the percentage of injected dose per gram of tissue (% ID/g). Statistical analysis was performed using an independent two-population *t*-test (significance level *p* = 0.05) and Origin 6.1 software (Northampton, MA, USA).

### 2.7.6. Micro-Positron Emission Tomography/Computer Tomography Imaging {#sec2dot7dot6-biomolecules-09-00091}

Micro-Positron Emission Tomography/computer tomography (MicroPET/CT) imaging studies were carried out using an Inveon microPET/CT scanner (Siemens Preclinical Solutions, Knoxville, TN, USA). Healthy female BALB/c mice were injected intravenously with 5 MBq of either \[^89^Zr\]Zr-FSC(succ)~3~ (16 µg, *n* = 1) or \[^89^Zr\]Zr-TAFC (13 µg, *n* = 1). MicroPET/CT images were acquired under general anesthesia (isoflurane/O~2~) for 20 min. Imaging data were recorded via static scans at 80 min and 24 h p.i. The microPET/CT scans were reconstructed and merged with OSEM3D-SPMAP (PET, matrix size 256 × 256) and Feldkamp (CT, Shepp Logan filter). For evaluation of bone uptake, image-based quantitation was carried out by selecting volumes of interest around each knee region and % ID/cm^3^ were calculated for both time points (VivoQuant image analysis software, Invicro LLC, Boston, MA, USA) and expressed as mean values of left and right knees to compare both compounds.

3. Results {#sec3-biomolecules-09-00091}
==========

3.1. Synthesis {#sec3dot1-biomolecules-09-00091}
--------------

The straightforward synthesis of FSC(succ)~2~AA and FSC(succ)~3~ is shown in [Scheme 1](#biomolecules-09-00091-sch001){ref-type="scheme"}. Fusarinine C was reacted with succinic anhydride at pH 4.5 resulting in FSC(succ)~3~ and FSC(succ)~2~ in satisfactory yields of 88 ± 4.0% and 43 ± 4.5%, respectively. The unreacted amine group of FSC(succ)~2~ was further derivatized with a molar excess of acetic anhydride resulting in the final compound FSC(succ)~2~AA. High-performance liquid chromatograms demonstrated the purity of compounds above 96%, see [Supplementary Materials, Figures S1--S3](#app1-biomolecules-09-00091){ref-type="app"}. Zr-FSC(succ)~2~AA and Zr-FSC(succ)~3~ were produced by the complexation of precursors with a molar excess of ZrCl~4~ in 0.1 M HCl solution at pH 1 within 5 min. Reaction of excess of precursor with ZrCl~4~ (0.1 eq) showed a comparable reaction efficiency. ESI-MS demonstrated not only the metal-to-ligand ratio of 1:1 but also the high-purity of Zr-complexes by analyzing the distinctive isotopic ratios of zirconium, see [Supplementary Materials, Figures S4--S6](#app1-biomolecules-09-00091){ref-type="app"}.

3.2. ^89^Zr-Labeling {#sec3dot2-biomolecules-09-00091}
--------------------

The ^89^Zr-labeling procedure of DFO, TAFC, FSC(succ)~2~AA and FSC(succ)~3~ was as previously described \[[@B23-biomolecules-09-00091]\]. Quantitative radiolabeling was achieved in HEPES buffer at RT between pH 6.8 to 7.2 within 90 min. Quality control was carried out by analytical RP-HPLC (instead of the instant thin-layer chromatography (ITLC) method for \[^89^Zr\]Zr-DFO and \[^89^Zr\]Zr-TAFC reported previously in which \[^89^Zr\]Zr-DFO and \[^89^Zr\]Zr-TAFC remain at the origin and free \[^89^Zr\]Zr^4+^ migrates with the solvent front). This change was due to the undesirable spread of \[^89^Zr\]Zr-FSC(succ)~2~AA and \[^89^Zr\]Zr-FSC(succ)~3~ along the ITLC strips.

3.3. Ex Vitro Characterization {#sec3dot3-biomolecules-09-00091}
------------------------------

Fusarinine C(succ)~2~AA and FSC(succ)~3~ showed high solubility in water, which is comparable to TAFC but different from recently reported novel octadentate chelators which seem to have poor solubility \[[@B9-biomolecules-09-00091]\]. The lower logD values of \[^89^Zr\]Zr-FSC(succ)~2~AA and \[^89^Zr\]Zr-FSC(succ)~3~ (−3.3 ± 0.1 and −3.5 ± 0.4, respectively) indicate higher hydrophilic properties than \[^89^Zr\]Zr-DFO and \[^89^Zr\]Zr-TAFC (−3.0 ± 0.1 and −2.0 ± 0.0, respectively). All radioligands showed high stability in PBS and human serum over a period of seven days and no demetallation was observed. The low protein-bound activity (\<10%) over the whole monitoring period further confirmed the stability of radioligands in human serum. The logD, protein binding and stability in human serum data for \[^89^Zr\]Zr-FSC(succ)~2~AA and \[^89^Zr\]Zr-FSC(succ)~3~ are summarized in [Table 1](#biomolecules-09-00091-t001){ref-type="table"} and compared with previously reported data of \[^89^Zr\]Zr-DFO and \[^89^Zr\]Zr-TAFC \[[@B23-biomolecules-09-00091]\].

Acid dissociation experiments and transchelation studies were performed to compare the relative kinetic inertness of \[^89^Zr\]Zr-DFO, \[^89^Zr\]Zr-TAFC, \[^89^Zr\]Zr-FSC(succ)~2~AA and \[^89^Zr\]Zr-FSC(succ)~3~. Data of dissoctiation experiments are summarized in [Figure 3](#biomolecules-09-00091-f003){ref-type="fig"}. Briefly, at pH 7, \[^89^Zr\]Zr-TAFC, \[^89^Zr\]Zr-FSC(succ)~2~AA and \[^89^Zr\]Zr-FSC(succ)~3~ revealed excellent resistance to transchelation over seven days, in contrast to that for \[^89^Zr\]Zr-DFO where almost 60% transchelation occurred, see [Figure 3](#biomolecules-09-00091-f003){ref-type="fig"}A. At pH 6, \[^89^Zr\]Zr-FSC(succ)~3~ remained intact (97.8%), being more stable than \[^89^Zr\]Zr-TAFC (94.4%) and significantly higher than \[^89^Zr\]Zr-FSC(succ)~2~AA (76%), see [Figure 3](#biomolecules-09-00091-f003){ref-type="fig"}B. At pH 4, the difference in stability of \[^89^Zr\]Zr-FSC(succ)~3~ and \[^89^Zr\]Zr-TAFC was more pronounced (87.9 vs. 70.3% of intact complex, respectively, at day 7), see [Figure 3](#biomolecules-09-00091-f003){ref-type="fig"}C.

Transchelation experiments are shown in [Figure 4](#biomolecules-09-00091-f004){ref-type="fig"} and were performed by incubating: (A) \[^89^Zr\]Zr-DFO in a 1000-fold molar excess of FSC(succ)~2~AA or FSC(succ)~3~, or (B) \[^89^Zr\]Zr-TAFC, \[^89^Zr\]Zr-FSC(succ)~2~AA and \[^89^Zr\]Zr-FSC(succ)~3~ incubated in a 1000-fold molar excess of DFO. The transchelation ratio of (A) ^89^Zr from \[^89^Zr\]Zr-DFO to FSC(succ)~2~AA and FSC(succ)~3~ or (B) from \[^89^Zr\]Zr-TAFC, \[^89^Zr\]Zr-FSC(succ)~2~AA and \[^89^Zr\]Zr-FSC(succ)~3~ to DFO was easily calculated due to the significant difference of the retention time of radioligands. Almost quantitative transchelation of ^89^Zr from \[^89^Zr\]Zr-DFO to FSC(succ)~2~AA or FSC(succ)~3~ was observed within 1 h. In contrast, \[^89^Zr\]Zr-TAFC, \[^89^Zr\]Zr-FSC(succ)~2~AA and \[^89^Zr\]Zr-FSC(succ)~3~ showed a stronger resistance to transchelation to DFO. After 7 days, \[^89^Zr\]Zr-FSC(succ)~3~ showed the highest kinetic inertness (62.1% of intact complex) compared with \[^89^Zr\]Zr-TAFC and \[^89^Zr\]Zr-FSC(succ)~2~AA (39.8% and 30.8% of intact complex, respectively).

3.4. Biodistribution Study and Micro-Positron Emission Tomography/Computer Tomography (microPET/CT) Imaging {#sec3dot4-biomolecules-09-00091}
-----------------------------------------------------------------------------------------------------------

Based on the above-mentioned results, \[^89^Zr\]Zr-FSC(succ)~3~ and \[^89^Zr\]Zr-TAFC were further compared in vivo. Biodistribution data of \[^89^Zr\]Zr-FSC(succ)~3~ and \[^89^Zr\]TAFC are presented in [Figure 5](#biomolecules-09-00091-f005){ref-type="fig"}. Both radioligands show rapid clearance from the body, mainly through the kidneys and a rather low uptake, especially, in bones. A relatively slower blood clearance for \[^89^Zr\]Zr-FSC(succ)~3~ than for \[^89^Zr\]Zr-TAFC was observed (0.11 ± 0.08 vs. 0.05 ± 0.01% ID/g). Correspondingly, activity in heart (0.28 ± 0.08% ID/g), lung (0.21 ± 0.04% ID/g), muscle (0.25 ± 0.07% ID/g), and bone (0.24 ± 0.04% ID/g) were also higher. The microPET/CT images of the BALB/c mouse at 80 min p.i. and 24 h p.i. injected with either \[^89^Zr\]Zr-FSC(succ)~3~ or \[^89^Zr\]Zr-TAFC further confirmed similar rapid pharmacokinetics, see [Figure 6](#biomolecules-09-00091-f006){ref-type="fig"}, three-dimensional images: [Supplementary Materials, Figures S7--S10](#app1-biomolecules-09-00091){ref-type="app"}. The kidneys and bladder were the primarily visible structures, which is related to excretion and kidney retention. At 80 min p.i. \[^89^Zr\]Zr-FSC(succ)~3~ showed some gall bladder activity and some minor activity in the small bowel which disappeared in the late images. More importantly, no bone uptake was observed, confirming the high in vivo stability of both compounds. An image-based quantitative comparison of bone uptake in the knee of mice revealed an even lower uptake of \[^89^Zr\]Zr-FSC(succ)~3~ with 0.083 and 0.026% ID/cm^3^ and of \[^89^Zr\]Zr-TAFC with 0.040 and 0.016% ID/cm^3^ at 80 min and 24 h, respectively, underlining the high in vivo stability of both chelates.

4. Discussion {#sec4-biomolecules-09-00091}
=============

The high potential of FSC as a novel multivalent ^89^Zr-bifunctional chelator was demonstrated by our group recently \[[@B23-biomolecules-09-00091]\]. However, the six coordinating oxygens of FSC do not coordinatively saturate the Zr^4+^. In addition, three of the functionalities of FSC may limit its application to the macromolecules, especially antibodies. On this basis, we were interested in designing novel chelators based on FSC by introducing two or three carboxylic functional groups, which were expected to, on one hand, improve the stability of complexation by saturating the coordination sphere of \[^89^Zr\]Zr^4+^ and, on the other hand, reduce the number of conjugation groups making them suitable for conjugation to mAbs.

As proof of concept, two or three succinic acid groups were introduced into the FSC skeleton and FSC(succ)~2~, FSC(succ)~2~AA and FSC(succ)~3~ were synthesized with satisfactory yields. In our previous report, we discovered that iron protection is required for coupling FSC with targeting vectors \[[@B23-biomolecules-09-00091]\]. However, the present study revealed that FSC can couple active groups such as anhydride groups at acidic pH, which provides a simpler conjugation approach. Moreover, the successful synthesis of FSC(succ)~2~ and FSC(succ)~2~AA opens a way to apply it to mAbs. FSC(succ)~2~, which has only one free amine functionality left, possesses the potential to couple mAbs with an activated group resulting in a monomeric FSC(succ)~2~-mAb.

In this study, the rapid and quantitative complexing of FSC(succ)~2~AA and FSC(succ)~3~ with ZrCl~4~ was reported and confirmed by ESI-MS. In our previous papers, we reported simple quantitative binding of ZrCl~4~ with TAFC at acidic pH (1--5) within 5 min \[[@B23-biomolecules-09-00091]\] and quantitative labeling of TAFC with ^89^Zr-oxalate using acetate buffer \[[@B27-biomolecules-09-00091]\]. On the basis of these findings, we can anticipate that \[^89^Zr\]ZrCl~4~ may be a better choice for labeling FSC derivatives in acetate buffer at appropriate pH. The advantage of \[^89^Zr\]ZrCl~4~ over ^89^Zr-oxalate lies not only in the shorter labeling time but also in avoiding the use of highly concentrated oxalate solution which potentially can result in the production of solid calcium oxalate causing kidney damage. In contrast to HEPES buffer, which requires additional quality control before clinical application, acetate buffer is entirely pharmaceutically compatible. For better understanding the exact coordination structures as well as their influence on stability, the preparation of single crystals of Zr-TAFC, Zr-FSC(succ)~2~AA and Zr-FSC(succ)~3~ for X-ray Diffraction was explored using different strategies; however, this failed. Multivalent hydroxamates seem not to crystallize easily, and this may be the reason that Zr(Me-AHA)~4~ is the only successfully crystallized Zr-hydroxamate compound \[[@B11-biomolecules-09-00091]\].

To assess the relative kinetic inertness of \[^89^Zr\]Zr-DFO, \[^89^Zr\]Zr-TAFC, \[^89^Zr\]Zr-FSC(succ)~2~AA and \[^89^Zr\]Zr-FSC(succ)~3~, acid dissociation experiments were performed under acidic conditions. At pH 4, \[^89^Zr\]Zr-FSC(succ)~3~ was the most kinetically inert compound to acid dissociation for seven days, with \[^89^Zr\]Zr-TAFC showing moderate stability, followed by \[^89^Zr\]Zr-FSC(succ)~2~AA, and \[^89^Zr\]Zr-DFO totally decomposing on day 3. Transchelation studies showed the same but more pronounced trend. \[^89^Zr\]Zr-DFO showed total transchelation within 1 h whereas other ^89^Zr-complexes only showed limited transchelation after seven days. The improved stability and kinetic inertness of \[^89^Zr\]Zr-FSC(succ)~3~, \[^89^Zr\]Zr-TAFC, and \[^89^Zr\]Zr-FSC(succ)~2~AA over \[^89^Zr\]Zr-DFO were attributed to the macrocyclic structure. The superior stability of \[^89^Zr\]Zr-FSC(succ)~3~ over \[^89^Zr\]Zr-TAFC and \[^89^Zr\]Zr-FSC(succ)~2~AA may be as a result of the higher coordination number and better coordination configuration. The lower stability of \[^89^Zr\]-Zr-FSC(succ)~2~AA compared to \[^89^Zr\]Zr-TAFC may be related to the loss of the symmetrical structure. However, the superior stability of \[^89^Zr\]Zr-FSC(succ)~2~AA over \[^89^Zr\]Zr-DFO highlights the potential of FSC(succ)~2~ as a monomeric chelator in the development of novel ^89^Zr-tracers.

A direct biodistribution comparison revealed a much slower blood clearance of \[^89^Zr\]Zr-FSC(succ)~3~ than \[^89^Zr\]Zr-TAFC, resulting in a higher uptake in all major organs. Notably, the bone activity of \[^89^Zr\]Zr-FSC(succ)~3~ was significantly higher than that of \[^89^Zr\]Zr-TAFC, possibly mainly reflecting the slower clearance rather than being actual bone uptake. Even though different time points were chosen for an imaging study, this was confirmed by images at 24 h p.i. showing both radioligands without visible bone uptake. \[^89^Zr\]Zr-FSC(succ)~3~ also showed some hepatobiliary excretion in microPET/CT images at the early time point of 80 min, which was not depicted at 24 h p.i. and in the 6 h p.i. biodistribution study. The overall difference in biodistribution may be attributed to the difference in the chelate-radiometal net charge and polarity. \[^89^Zr\]Zr-TAFC possesses a positive net charge while \[^89^Zr\]Zr-FSC(succ)~3~ shows an overall negative charge character, which may potentially influence the excretion patterns of radiotracers. However, the difference in clearance rates between \[^89^Zr\]Zr-FSC(succ)~3~ and \[^89^Zr\]Zr-TAFC should not be a concern in its final application. Upon conjugation to a targeting biomolecule, the pharmacokinetics of the \[^89^Zr\]Zr-FSC(succ)~3~ complex will be completely superseded by those of biomacromolecules. Higher kidney and lower liver uptake compared to \[^89^Zr\]Zr-TAFC indicates a renal excretion pathway, which is consistent with the higher hydrophilicity of \[^89^Zr\]Zr-FSC(succ)~3~.

5. Conclusions {#sec5-biomolecules-09-00091}
==============

In our study, three FSC derivatives were synthesized and labeled with zirconium-89. \[^89^Zr\]Zr-FSC(succ)~2~AA showed superiority over \[^89^Zr\]Zr-DFO in vitro. Furthermore, \[^89^Zr\]Zr-FSC(succ)~3~ revealed the best stability and inertness in comparison to \[^89^Zr\]Zr-DFO, \[^89^Zr\]Zr-TAFC and \[^89^Zr\]Zr-FSC(succ)~2~AA. The superiority of FSC(succ)~3~ was attributed to the higher coordination number and better coordination configuration. The successful synthesis of FSC(succ)~2~ and FSC(succ)~2~AA highlights the potential of FSC(succ)~2~ as a monovalent ^89^Zr-chelator for the conjugation to mAbs. Further studies of FSC(succ)~2~-conjugated mAbs, especially in vivo, in comparison with their DFO counterparts and potentially other novel Zr-chelators, are needed to show the true potential of this approach for Immuno-PET.

The following are available online at <https://www.mdpi.com/2218-273X/9/3/91/s1>, Figure S1: HPLC chromatogram of purified FSC(succ)~2~, Figure S2: HPLC chromatogram of purified FSC(succ)~2~AA, Figure S3: HPLC chromatogram of purified FSC(succ)3, Figure S4: The ESI-MS of \[^nat^Zr\]FSC(succ)~3~, Figure S5: The ESI-MS of \[^nat^Zr\]FSC(succ)~2~AA, Figure S6: The calculated isotope pattern for C~45~H~63~N~6~O~21~Zr (\[^nat^Zr\]FSC(succ)~3~), Figure S7: 3D microPET/CT images of \[^89^Zr\]Zr-FSC(succ)~3~ in a mouse 80min p.i., Figure S8: 3D microPET/CT images of \[^89^Zr\]Zr-FSC(succ)~3~ in a mouse 24h p.i., Figure S9: 3D microPET/CT images of \[^89^Zr\]Zr-TAFC in a mouse 80min p.i., Figure S10 3D microPET/CT images of \[^89^Zr\]Zr-TAFC in a mouse 24h p.i.

###### 

Click here for additional data file.
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![Structures of desferrioxamine B (DFO), fusarinine C (FSC), triacetylfusarinine C (TAFC), FSC(succ)~2~, FSC(succ)~2~AA and FSC(succ)~3~.](biomolecules-09-00091-g001){#biomolecules-09-00091-f001}

![Postulated coordination structures of Zr-FSC(succ)~2~AA (**A**) and Zr-FSC(succ)~3~ (**B**).](biomolecules-09-00091-g002){#biomolecules-09-00091-f002}

![Synthesis strategies of FSC(succ)~3~ and FSC(succ)~2~AA.](biomolecules-09-00091-sch001){#biomolecules-09-00091-sch001}

###### 

Acid dissociation studies of \[^89^Zr\]Zr-DFO (─⬛─), \[^89^Zr\]Zr-TAFC (─●─), \[^89^Zr\]Zr-FSC(succ)~2~AA (─▲─) and \[^89^Zr\]Zr-FSC(succ)~3~ (─▼─) in a 1000-fold molar excess of EDTA solution at pH 7 (**A**), pH 6 (**B**), and pH 4 (**C**).

![](biomolecules-09-00091-g003a)

![](biomolecules-09-00091-g003b)

![Transchelation studies: Percent of intact \[^89^Zr\]Zr-DFO (─⬛─) incubated in a 1000-fold molar excess of FSC(succ)~3~ or FSC(succ)~2~AA, and \[^89^Zr\]Zr-TAFC (─●─), \[^89^Zr\]Zr-FSC(succ)~2~AA (─▲─) and \[^89^Zr\]Zr-FSC(succ)~3~ (─▼─) incubated in a 1000-fold excess of DFO.](biomolecules-09-00091-g004){#biomolecules-09-00091-f004}

![Comparison of biodistribution data of \[^89^Zr\]Zr-FSC(succ)~3~ (4.8 µg, 1.5 MBq, *n* = 4) with \[^89^Zr\]Zr-TAFC (4 µg, 1.5 MBq, *n* = 4) at 6 h post infection (p.i.) in BALB/c mice. \* indicates significant differences between the two compounds (*p* \< 0.05).](biomolecules-09-00091-g005){#biomolecules-09-00091-f005}

![Micro-positron emission tomography/computer tomography images at 80 min p.i. and 24 h p.i. of BALB/c mice injected with either \[^89^Zr\]Zr-FSC(succ)3 or \[^89^Zr\]Zr-TAFC. Red arrow indicator: kidneys; blue arrow indicator: bladder. The single focal accumulation in the image of \[^89^Zr\]Zr-FSC(succ)3 80 min p.i. is related to gall bladder activity, additionally some activity in small bowel appears, which disappears at 24 h p.i.](biomolecules-09-00091-g006){#biomolecules-09-00091-f006}
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###### 

LogD, protein binding, and stability in human data for \[^89^Zr\]Zr-DFO, \[^89^Zr\]Zr-TAFC, \[^89^Zr\]Zr-FSC(succ)~2~AA and \[^89^Zr\]Zr-FSC(succ)~3~.

  ^89^Zr-Complex                Log D        Incubation Time (days)   Protein Binding (%)   Stability in Human Serum (%)
  ----------------------------- ------------ ------------------------ --------------------- ------------------------------
  \[^89^Zr\]Zr-DFO              −3.0 ± 0.1   7                        8.7 ± 1.0             99.3
  \[^89^Zr\]Zr-TAFC             −2.0 ± 0.0   7                        6.8 ± 0.5             99.5
  \[^89^Zr\]Zr-FSC(succ)~2~AA   −3.3 ± 0.1   7                        5.9 ± 1.6             99.4
  \[^89^Zr\]Zr-FSC(succ)~3~     −3.5 ± 0.4   7                        8.3 ± 3.5             99.5
